Prodduturi Prathima, Perry Anamarija M, Aoun Patricia, Weisenburger Dennis D, Akhtari Mojtaba
Department of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE 68198-7680, USA.
J Oncol Pharm Pract. 2012 Dec;18(4):440-4. doi: 10.1177/1078155212438112. Epub 2012 Mar 7.
Nilotinib is a potent tyrosine kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL), which has been approved as front-line therapy for newly diagnosed chronic myeloid leukemia in chronic phase and as second-line therapy after imatinib failure in chronic or accelerated phase chronic myeloid leukemia. Tyrosine kinase inhibitors have been associated with myelosuppression and grade 3 or grade 4 cytopenias are not uncommon in chronic myeloid leukemia patients treated with these drugs. There are a few reports of imatinib-associated bone marrow aplasia, but to our knowledge only one reported case of bone marrow aplasia associated with nilotinib. Herein, we report a 49-year-old male patient with chronic phase chronic myeloid leukemia, who developed severe bone marrow aplasia due to nilotinib. Possible mechanisms for this significant adverse drug reaction are discussed along with a review of literature.
尼洛替尼是一种有效的酪氨酸激酶抑制剂，可抑制断裂点簇集区-阿贝尔森（BCR-ABL），已被批准作为新诊断的慢性期慢性髓性白血病的一线治疗药物，以及在慢性或加速期慢性髓性白血病中伊马替尼治疗失败后的二线治疗药物。酪氨酸激酶抑制剂与骨髓抑制有关，在接受这些药物治疗的慢性髓性白血病患者中，3级或4级血细胞减少并不罕见。有一些关于伊马替尼相关骨髓再生障碍的报道，但据我们所知，只有一例报告的骨髓再生障碍与尼洛替尼有关。在此，我们报告一名49岁的慢性期慢性髓性白血病男性患者，他因尼洛替尼出现了严重的骨髓再生障碍。本文讨论了这种严重药物不良反应的可能机制，并对相关文献进行了综述。
